SCHEMBL1484465

SCHEMBL1484465

COc1ccc(CNC(=O)CCBr)cc1

nearest known ligand 0.67

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.63
NPC1 O15118 1/20 0.61
GAA P10253 2/20 0.61
TSHR P16473 1/20 0.61
MEN1 O00255 1/20 0.60
KMT2A Q03164 1/20 0.60
GRK2 P25098 1/20 0.60
PKM P14618 2/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
CNR1 P21554 2/20 0.58
TRPV1 Q8NER1 1/20 0.56
CNR2 P34972 1/20 0.56
POLB P06746 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14060748 0.88 CNR1 (0.67) ALDH1A1NPC1GAATSHRMEN1
SCHEMBL27672313 0.87 NPC1 (0.65) ALDH1A1NPC1GAATSHRMEN1
SCHEMBL2176443 0.87 NPC1 (0.65) ALDH1A1NPC1GAATSHRMEN1
SCHEMBL12127405 0.85 CNR1 (0.67) ALDH1A1NPC1GAATSHRMEN1
SCHEMBL24590138 0.84 ALDH1A1 (0.64) ALDH1A1NPC1GAATSHRMEN1
SCHEMBL13461105 0.84 MEN1 (0.64) ALDH1A1NPC1GAATSHRMEN1
SCHEMBL14281354 0.84 TSHR (0.69) ALDH1A1NPC1GAATSHRMEN1
SCHEMBL7357569 0.84 MEN1 (0.64) ALDH1A1NPC1GAATSHRMEN1
SCHEMBL5331532 0.84 ALDH1A1 (0.68) ALDH1A1NPC1GAATSHRMEN1
SCHEMBL4901981 0.83 MEN1 (0.63) ALDH1A1NPC1GAATSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130078256-A1 NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2013-03-28 US disclosed
US-20130078256-A1 NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2013-03-28 US disclosed
US-8334295-B2 Pyrimidine derivatives as HIV reverse transcriptase inhibitors KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2012-12-18 US disclosed
US-8334295-B2 Pyrimidine derivatives as HIV reverse transcriptase inhibitors KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2012-12-18 US disclosed
US-20110076276-A1 Novel HIV reverse transcriptase inhibitors GILEAD SCIENCES, INC. (US) 2011-03-31 US disclosed
US-20110076276-A1 Novel HIV reverse transcriptase inhibitors GILEAD SCIENCES, INC. (US) 2011-03-31 US disclosed
EP-2167476-A2 NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS Korea Research Institute Of Chemical Technology (KR) 2010-03-31 EP disclosed
WO-2009005674-A2 NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS GILEAD SCIENCES, INC. (US) 2009-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110076276-A1 Novel HIV reverse transcriptase inhibitors POLR2E, POLR1E, POLR2H ALDH1A1 1800/4885NPC1 664/4885GAA 418/4885
US-20130078256-A1 NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS POLR2E, POLR1E, POLR2H ALDH1A1 1800/4885NPC1 664/4885GAA 418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.